RG-7351 is a trace amine-associated receptor 1 (TAAR1) partial agonist that is or was under development for the treatment of major depressive disorder.
[1][2][3][4] It reached phase 1 clinical trials for this indication in 2010.
[1][2][4] However, as of November 2023, no further recent development has been reported since July 2016.
[1] The drug was developed by Hoffmann-La Roche.
This pharmacology-related article is a stub.